Ibio, Inc. · NASDAQ:IBIO
Ibio — Investor Presentation (October 2022)
23 slides from Ibio's investor presentation, Oct 3, 2022
Slide 1: Growing Tomorrow's Biologics: Corporate Presentation
GrowingTomorrow’s Biologics CORPORATE PRESENTATION October 2022 Tom Isett, Chairman & CEO © 2022 iBio, Inc. All Rights Reserved.
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continu
Slide 3: iBio: A Biopharmaceutical Discovery & Development Company
3 iBio: A Biopharmaceutical Discovery & Development Company Proprietary Pipeline FastPharming® Manufacturing Platform Proprietary plant-based protein expression system Focused on Immuno-Oncology Patented AI-Driven Discovery Engine Identification and engineering of hard-to-target epitopes Glycaneerin
Slide 4: Platforms
Platforms
Slide 5: Unique Solutions for Some of the Industry's Biggest Problems
5 Unique Solutions for Some of the Industry’s Biggest Problems Biopharmaceutical Development Challenges Our Solutions 1 2 3 SO L U T I O N S Discovery Engine Program Failures Time / Cost Biomanufacturing Only ~5 in 5,000 drug concepts reach the >1 year & ~$3-7M for scalable bioprocess & Drug industr
Slide 6: RubrYc AI-Powered Discovery Engine: Drug Discovery for Hard-to-Target Binding Sites
6 RubrYc AI-Powered Discovery Target" Binding Sites Engine: Drug Discovery for ”Hard-to-The Problems Our Solutions RubrYc® Discovery Engine* Subdominant Epitopes Sites often missed with standard screening Conformational Epitopes Binding sites spread across amino acid chains Better Antibody Designs à
Slide 7: End-to-End Computational Biology System for Large-Molecule Drug Candidates
7 End-to-End Computational Biology System for Enhanced Identification & Engineering of Large-Molecule Drug Candidates Engineered Epitope Optimize with StableHuTM AI Engine Human Optimized mAb Lead Pool Epitope Antibody Hits On-Epitope Clinical Candidate Targeting Engine RubrYcHuTM Library 1 2 3 Epit
Slide 8: FastPharming: Green Protein Expression System
8 FastPharming: Green Protein Expression System 1 130,000 sf Facility 2 3 4 5 Seeding & Growth Bacterial Infiltration (Transient Transfection) Protein Production Harvesting Purification & Vialing Gene Cloning Mobilization
Slide 9: The Speed & Scalability of FastPharming
9 The Speed & Scalability of FastPharming Potentially Enables a Faster, More Efficient Path to the Clinic (Bacterial) ubstance brings the capability to avoid the significant cost and time associated with selecting, developing & banking mammalian cell lines Time to Drug Substance may vary and does no
Slide 10: iBio Platforms Potentially Enable More Promising Candidates to Reach the Clinic, Faster
10 iBio Platforms Potentially Enable More Promising Candidates to Reach the Clinic, Faster RubrYc Discovery Engine + Current Drug Development Challenge + GlycaneeringTM Technology ycan ~4x 40 year s 0 Standard 1https://www.researchgate.net/publication/265288848_The_Global_Biomedical_Industry_Preserv
Slide 11: Reducing Single-Use Plastic Disposables in Upstream Processing
11 Reducing Single-Use Plastic Disposables in Upstream Processing The FastPharming Bioreactor uses all-natural raw materials >85% of pre-commercial bioprocesses involve VS single-use plastic disposables1 Seeds Stone Wool Purified Water 117th Annual Report and Summary of Biopharmaceutical Manufacturi
Slide 12: Pipeline Growth Driven by Immuno-Oncology Program
12 Pipeline Growth Driven by Immuno-Oncology Program Fibrotic Diseases IBIO-100 * Developed using the RubrYc Discovery Engine ANIMAL HEALTHPROGRAMSPOCPRE-CLINICALCLINICAL DEVPRODUCT REGISTRATION Infectious DiseaseIBIO-400Classical Swine Fever Vaccine HUMAN HEALTHPROGRAMSEARLY DISCOVERYLATE DISCOVERY
Slide 13: Immuno-Oncology
Immuno-Oncology
Slide 14: Deploying AI-based Target ID/Engineering & Glycaneering for Anti-Cancer Candidates
14 Deploying AI-based Target ID/Engineering & Glycaneering to Create More, Higher-Quality, Anti-Cancer Candidates iBio Discovery & Pipeline More shots-on-goal, 1 Dev Approach sooner AI Discovery Platform Drug Discovery Clinical Preclinical Identifying failures 2 earlier, saving costs Accelerating de
Slide 15: IBIO-101 Stimulates Anti-tumor Immunity via anti-CD25 Treg Depletion
15 IBIO-101 (Lead Depletion Program) Stimulates Anti-tumor Immunity via anti-CD25 Treg IBIO-101 IL-2 signaling Natural Killer Cell IL-2 ADCC Teff Tumor JAK JAK JAK JAK Proliferation Treg Preferential Treg depletion 2nd gen IL-2 sparing anti-CD25 antibody electively targets Tregs without blocking IL-
Slide 16: Characteristics of Plant and CHO Made Molecules are Comparable
16 Characteristics of Plant and CHO Made Molecules are Comparable IBIO-101 demonstrates equivalent binding kinetics compared with RTX-003 Phan, et al. "Plant-Based Expression and Glyco-Engineering of Novel IL-2 Signaling Permissive Anti-CD25 Antibodies for Effective Treg Depletion in Cancer” THE R A
Slide 17: FastPharming and CHO Molecules Bind Potently to CD25
17 FastPharming and CHO Produced Molecules Bind Potently to CD25, Which is Commonly Expressed by Treg Cells IBIO-101 and RTX-003 show nearly identical binding to recombinant human and non-human primate CD25, but don’t cross react with recombinant mouse CD25 protein Phan, et al. "Plant-Based Expressi
Slide 18: Molecules Bind CD25-Positive Tumor Cells and Don't Interfere with IL-2 Signaling
18 FastPharming and CHO Produced Molecules Bind to CD25-Positive Human Tumor Cells; and Don't Interfere with Important IL-2 Signaling RTX-003 EC = 0.14 ng/mL IBIO-101 and RTX-003 bind to SUDHL1 human lymphoma cells and don’t interfere with IL-2 stimulated STAT5 activation Phan, et al. "Plant-Based E
Slide 19: FastPharming and CHO Molecules Have Similar Potency in Cancer Cell Killing
19 FastPharming and CHO Produced Molecules Have Similar Potency and Efficacy in Cancer Cell Killing Assays Efficacy and potency of IBIO-101 and RTX-003 are comparable in antibody-dependent cellular cytotoxicity assays using a reporter assay or primary human PBMC Phan, et al. "Plant-Based Expression
Slide 20: In Summary
·I a"10 In Summary
Slide 21: Our Leadership Team Brings Drug Development & Bioprocessing Experience
21 Our Leadership Team Brings Drug Development & Bioprocessing Experience Marc Banjak GC Lisa Middlebrook CHRO Robert Lutz, MBA CFBO Martin Brenner, DVM, Ph.D. CSO Tom Isett CEO & Chairman
Slide 22: Strong and Growing IP Estate Provides Exclusivity for iBio's Pipeline
22 Strong and Growing IP Estate Provides Exclusivity for iBio’s Pipeline Applications Active Applications Issued Patents Patent Protection Includes: • • • • Intellectual property [IP] around iBio’s biopharmaceutical candidates IP related to the Drug Discovery platform (including Notice of Allowance
Slide 23: iBio: Leveraging Capabilities
23 iBio: Leveraging Capabilities Combing platforms to create a biotech company with its own end-to-end discovery capabilities Pipeline of promising immunotherapy candidates, with a focus on immuno-oncology Discovery Pipeline Partnering Leveraging patented platforms for both in-licensing and out-lice